Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma Journal Article

Authors: Saenger, Y. M.; Li, Y.; Chiou, K. C.; Chan, B.; Rizzuto, G.; Terzulli, S. L.; Merghoub, T.; Houghton, A. N.; Wolchok, J. D.
Article Title: Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma
Abstract: Passive immunization with monoclonal antibody TA99 targeting melanoma differentiation antigen tyrosinase-related protein-1 (Tyrp1; gp75) and active immunization with plasmid DNA encoding altered Tyrp1 both mediate tumor immunity in the B16 murine melanoma model. We report here that TA99 enhances Tyrp1 DNA vaccination in the treatment of B16 lung metastases, an effect mediated by immunologic mechanisms as Tyrp1 has no known role in regulating tumor growth. TA99 is shown to increase induction of anti-Tyrp1 CD8+T-cell responses to DNA vaccination against Tyrp1 as assessed by IFN-γ ELISPOT assays. Immunohistochemistry studies reveal that TA99 localizes rapidly and specifically to B16 lung nodules. Augmentation of T-cell responses is dependent on the presence of tumor as well as on activating Fc receptors. Furthermore, TA99 enhances DNA vaccination against a distinct melanoma antigen, gp100(pmel17/silver locus), improving antitumor efficacy, augmenting systemic CD8+ T-cell responses to gp100, and increasing CD8+ T-cell infiltration at the tumor site. Epitope spreading was observed, with CD8+ T-cell responses generated to Tyrp1 peptide in mice receiving gp100 DNA vaccination in the presence of TA99. Finally, we show that TA99 improves therapeutic efficacy of DNA vaccination combined with adoptive T-cell transfer in treatment of established subcutaneous B16 melanoma. In conclusion, TA99 enhances DNA vaccination against both the target antigen Tyrp1 and a distinct melanoma antigen gp100 in an Fc receptor-dependent mechanism, consistent with enhanced cross-presentation of tumor-derived antigen. Monoclonal antibodies should be tested as vaccine adjuvants in the treatment of cancer. ©2008 American Association for Cancer Research.
Keywords: immunohistochemistry; controlled study; unclassified drug; nonhuman; protein localization; cd8+ t lymphocyte; cd8-positive t-lymphocytes; mouse; animals; mice; glycoprotein gp 100; melanoma; lung neoplasms; animal experiment; animal model; gene locus; mice, inbred c57bl; mice, transgenic; monoclonal antibody; lung metastasis; lymphocyte activation; antibodies, monoclonal; dna; cellular immunity; immunotherapy; gamma interferon; cancer vaccines; membrane glycoproteins; epitope; melanoma b16; melanoma, experimental; adoptive transfer; tumor immunity; fc receptor; dna vaccine; melanoma antigen; monophenol monooxygenase; tumor growth; adjuvants, immunologic; enzyme linked immunospot assay; epitopes, t-lymphocyte; oxidoreductases; genetic code; vaccines, dna; immunotherapy, adoptive; dna immunization; expression vector; lung nodule; plasmid dna; monoclonal antibody ta99; receptors, fc; tyrosinase antibody; gene gun immunization
Journal Title: Cancer Research
Volume: 68
Issue: 23
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2008-12-01
Start Page: 9884
End Page: 9891
Language: English
DOI: 10.1158/0008-5472.can-08-2233
PUBMED: 19047169
PROVIDER: scopus
PMCID: PMC2742375
Notes: --- - "Cited By (since 1996): 9" - "Export Date: 17 November 2011" - "CODEN: CNREA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Jedd D Wolchok
    823 Wolchok
  2. Taha Merghoub
    297 Merghoub
  3. Alan N Houghton
    343 Houghton
  4. Yanyun Li
    29 Li
  5. Gabrielle A Rizzuto
    22 Rizzuto
  6. Karoline Chiayine Chiou
    1 Chiou